Success Metrics

Clinical Success Rate
90.6%

Based on 48 completed trials

Completion Rate
91%(48/53)
Active Trials
9(12%)
Results Posted
60%(29 trials)
Terminated
5(7%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_4
10
13%
Ph not_applicable
12
16%
Ph phase_1
20
26%
Ph phase_2
17
22%
Ph phase_3
16
21%

Phase Distribution

21

Early Stage

17

Mid Stage

26

Late Stage

Phase Distribution76 total trials
Early Phase 1First-in-human
1(1.3%)
Phase 1Safety & dosage
20(26.3%)
Phase 2Efficacy & side effects
17(22.4%)
Phase 3Large-scale testing
16(21.1%)
Phase 4Post-market surveillance
10(13.2%)
N/ANon-phased studies
12(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

48 of 56 finished

Non-Completion Rate

14.3%

8 ended early

Currently Active

9

trials recruiting

Total Trials

76

all time

Status Distribution
Active(11)
Completed(48)
Terminated(8)
Other(9)

Detailed Status

Completed48
unknown9
Recruiting8
Terminated5
Withdrawn3
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
76
Active
9
Success Rate
90.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.3%)
Phase 120 (26.3%)
Phase 217 (22.4%)
Phase 316 (21.1%)
Phase 410 (13.2%)
N/A12 (15.8%)

Trials by Status

withdrawn34%
recruiting811%
completed4863%
unknown912%
enrolling_by_invitation11%
terminated57%
active_not_recruiting11%
not_yet_recruiting11%

Recent Activity

Clinical Trials (76)

Showing 20 of 76 trialsScroll for more
NCT07227454Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Recruiting
NCT04246177Phase 3

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Completed
NCT00874237Phase 1

Staccato Loxapine Thorough QT/QTc Study

Completed
NCT02682511Phase 2

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Active Not Recruiting
NCT04368559Phase 3

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Completed
NCT06961708Phase 1

A Study of Fosmanogepix in Healthy Adult Chinese Subjects

Completed
NCT02905799Phase 3

Resveratrol in Knee Osteoarthritis

Completed
NCT05287256Phase 1

Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC

Completed
NCT04276259Phase 4

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Completed
NCT05988710Phase 4

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

Recruiting
NCT05865470Phase 1

Age-dependent Effects of Smoked and Oral Delta-9-THC

Recruiting
NCT05279742Phase 1

Enhancing the Natriuretic Peptide System in HFpEF

Enrolling By Invitation
NCT03567473Phase 3

Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study

Completed
NCT05324982Phase 1

Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants

Recruiting
NCT06978725Phase 2

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Recruiting
NCT03851835Phase 3

Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis

Completed
NCT05342194Phase 3

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Recruiting
NCT05558007Phase 2

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Recruiting
NCT05478863Early Phase 1

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

Completed
NCT06542445Phase 2

The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
76